Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:31 PM ET 8-K
M&A Deal Transportation & Logistics Systems, Inc. TLSS

Transportation & Logistics Systems M&A Deal Update

Transportation and Logistics Systems, Inc. filed an 8-K under Item 1.01 indicating the entry into a material definitive agreement. While the specific counterparty and deal value were not detailed in the provided text, the filing emphasizes the company's strategy of growing through the integration of acquisitions and the future acquisition of other businesses.

4:31 PM ET 8-K
Capital Raise Wetouch Technology Inc. WETH

Wetouch Technology Capital Raise of $38.8M

Wetouch Technology Inc. closed a private placement of 31,037,830 shares of common stock at $1.25 per share, generating gross proceeds of approximately $38.8 million. The transaction followed stockholder approval at a special meeting and was conducted as an unregistered sale of equity securities to Qixun Technology and Qihong Technology.

Value
$38.8M
Counterparty
Qixun Technology (Samoa) Limited and Qihong Technology (Samoa) Limited
4:31 PM ET 8-K
Nasdaq/NYSE Compliance Notice SCWorx Corp. WORX

SCWorx Nasdaq/NYSE Compliance Notice

SCWorx Corp. received a delisting decision from the Nasdaq Hearings Panel on September 17, 2026, due to a deficiency in publicly held shares following a reverse stock split. The company has requested reconsideration of the decision, claiming it cured the deficiency by issuing 449,860 shares in a private placement on September 16. To regain compliance, the company must also maintain a minimum bid price of $1.00 for 10 consecutive days by October 5, 2026.

Counterparty
Nasdaq
Term
through Oct 5, 2026
4:30 PM ET 8-K
M&A Deal StratCap Digital Infrastructure REIT, Inc.

StratCap Digital Infrastructure REIT M&A Deal Update

StratCap Digital Infrastructure REIT has concluded its previously announced strategic alternatives review process and decided not to pursue a sale of the company at this time. The board and its financial advisor engaged with potential counterparties but will now focus on managing the capital structure and evaluating other alternatives such as individual asset sales or special distributions.

4:29 PM ET 8-K
Loan & Debt Fifth Third Bancorp FITB

Fifth Third Bancorp $1.27B Debt Financing

Fifth Third Bancorp announced the expiration and results of its registered exchange offer for two series of senior notes totaling approximately $1.27 billion in principal. The company accepted $334.4 million of 4.000% Senior Notes due 2029 and $938.1 million of 5.982% Fixed-To-Floating Rate Senior Notes due 2030 for exchange into registered securities with substantially identical terms.

Value
$1.27B
4:28 PM ET 8-K
Capital Raise FMC Corp FMC

FMC Capital Raise of $403M

FMC Corporation completed a $403.2 million equity investment from Tessenderlo Group NV, which purchased approximately 30.3 million shares to reach a 20% ownership stake. As part of the deal, Tessenderlo Group gains the right to nominate one independent director to the FMC Board and is subject to a three-year lock-up period and customary standstill restrictions.

Value
$403M
Counterparty
Tessenderlo Group NV
4:27 PM ET 8-K
Capital Raise KKR Infrastructure Conglomerate LLC

KKR Infrastructure Conglomerate Capital Raise of $205M

KKR Infrastructure Conglomerate LLC sold approximately $205.3 million in unregistered Class I, Class S, and Class D shares for cash on September 1, 2026. This sale is part of a continuous private offering that has raised approximately $7,979 million since the company's inception in June 2023.

Value
$205M
Counterparty
Accredited and non-U.S. investors
4:24 PM ET 8-K
Business Update Raymond James Financial Inc RJF

Raymond James Financial Business Update

Raymond James Financial reported record assets under administration of $1.97 trillion for August 2026, representing a 16% increase year-over-year. The growth was driven by higher equity markets and net asset inflows from advisor retention and recruiting, while domestic cash sweep and Enhanced Savings Program balances reached $57.4 billion.

Term
August 2026
4:24 PM ET 8-K
Stock Plan Amendment Bath & Body Works, Inc. BBWI

Bath & Body Works Stock Plan Amendment

Bath & Body Works granted a performance stock unit (PSU) award with a target value of $10 million to its CEO, Daniel Heaf. The award is tied to rigorous stock price performance hurdles ranging from $40 to $100 per share over a four-year performance period and includes a total shareholder return (TSR) modifier.

Counterparty
Daniel Heaf
Term
4 years
4:22 PM ET 8-K
Capital Raise Teamshares Inc TMS

Teamshares Capital Raise of $223M

Teamshares Inc. closed a $222.75 million preferred equity investment through the sale of 225,000 shares of newly designated Series A Preferred Stock to affiliates of T. Rowe Price. The non-convertible, non-voting perpetual preferred stock was issued at $990 per share (a 1% original issue discount) and is intended to fund the company's programmatic acquisition strategy of small and medium-sized enterprises.

Value
$223M
Counterparty
T. Rowe Price Investment Management, Inc.
4:18 PM ET 8-K/A
Leadership Change Jacobs Solutions Inc. J

Jacobs Solutions Leadership Change

Jacobs Solutions Inc. reported a change in its senior leadership or board of directors under Item 5.02. The filing indicates the departure, election, or appointment of a director or certain senior officers, though specific names and roles were not detailed in the metadata.

4:18 PM ET 8-K
Loan & Debt Clarivate PLC CLVT

Clarivate $75M Debt Financing with Clarivate Science Holdings Corporation

Clarivate Plc's subsidiary, Clarivate Science Holdings Corporation, announced the pricing terms for its cash tender offer to repurchase up to $75 million in aggregate principal amount of its 3.875% Senior Secured Notes due 2028. The total consideration was set at $975.15 per $1,000 principal amount of notes, based on a fixed spread of 50 basis points over the reference U.S. Treasury yield.

Value
$75M
Counterparty
Clarivate Science Holdings Corporation
4:18 PM ET 8-K
M&A Deal Theravance Biopharma, Inc. TBPH

Theravance Biopharma M&A Deal with Zymeworks Inc.

Theravance Biopharma, Inc. completed its merger with Zymeworks Inc., becoming a wholly owned subsidiary of Zymeworks. Shareholders received $17.00 in cash per share plus one contingent value right (CVR) per share. The transaction was finalized on September 23, 2026, following the original merger agreement signed in June 2026.

Counterparty
Zymeworks Inc.
4:17 PM ET 8-K
Loan & Debt Covista Inc. CVSA

Covista $510M Debt Financing with Morgan Stanley Senior Funding, Inc.

Covista Inc. entered into Amendment No. 6 to its existing Credit Agreement to reprice $510 million in outstanding term loans. The amendment reduces the interest rate from Term SOFR plus 2.25% to Term SOFR plus 2.00%, effectively lowering the company's borrowing costs.

Value
$510M
Counterparty
Morgan Stanley Senior Funding, Inc.
4:16 PM ET 8-K
Loan & Debt Solaris Energy Infrastructure, Inc. SEI

Solaris Energy Infrastructure $1.25B Debt Financing with MUFG Securities Americas Inc.

Solaris Energy Infrastructure, LLC, a subsidiary of Solaris Energy Infrastructure, Inc., priced an upsized private placement of $1.25 billion in 7.000% Senior Notes due 2032. The offering was increased from an initial $1.0 billion and is expected to close on October 1, 2026. Net proceeds of approximately $1,227.2 million will be used for general corporate purposes, growth capital expenditures, and fees.

Value
$1.25B
Counterparty
MUFG Securities Americas Inc.
Term
through April 2032
4:16 PM ET 8-K
Leadership Change Farmers & Merchants Bancshares, Inc. FMFG

Farmers & Merchants Bancshares Leadership Change

Farmers and Merchants Bancshares, Inc. has elected Mark C. Krebs to its Board of Directors as a Class I director, effective September 21, 2026. Mr. Krebs previously served as the company's Treasurer and CFO until his retirement in June 2025 and will serve on the Asset/Liability, Investor Relations, and Nominating Committees.

Counterparty
Mark C. Krebs
4:16 PM ET 8-K
Investor Presentation Orange County Bancorp, Inc. OBT

Orange County Bancorp Investor Presentation

Orange County Bancorp, Inc. released an investor presentation deck to be reviewed with analysts and institutional investors at the Stephens Bank Forum 2026 on September 24, 2026. The materials provide updates on the company's operating and growth strategies, as well as its financial performance through the second quarter of 2026.

Counterparty
Stephens Bank Forum 2026
4:16 PM ET 8-K
Financial Results NeoVolta Inc. NEOV

NeoVolta Financial Results

NeoVolta reported fiscal year 2026 revenue of $13.3 million, a 58% increase year-over-year, despite a significant fourth-quarter revenue decline due to residential tax law changes. The company posted a GAAP net loss of $21.5 million for the year as it transitions into a multi-market energy storage platform through its NeoVolta Power manufacturing joint venture.

Term
FY2026
Earnings call
Sep 23, 2026, 5:00 PM ET
4:16 PM ET 8-K
Loan & Debt Jazz Pharmaceuticals plc JAZZ

Jazz Pharmaceuticals $1.9B Debt Financing with Bank of America, N.A.

Jazz Pharmaceuticals' subsidiary, Jazz Financing Lux S.à r.l., entered into a repricing amendment to its credit agreement to refinance $1.895 billion in outstanding term loans. The new Tranche B-3 Dollar Term Loans extend the maturity date from May 2028 to May 2033 and reduce the interest rate margin by 50 basis points to Term SOFR plus 1.75%.

Value
$1.9B
Counterparty
Bank of America, N.A.
Term
through May 2033
4:16 PM ET 8-K
Stock Plan Amendment Healthstream Inc HSTM

Healthstream Stock Plan Amendment

HealthStream's Compensation Committee approved special grants of time-based and performance-based restricted share units (RSUs) to its named executive officers under the 2022 Omnibus Incentive Plan. The grants, which include awards to CEO Robert A. Frist, Jr. and CFO Scott A. Roberts, are designed to incentivize future performance and retention with vesting schedules extending through 2030.

Term
4 years
4:15 PM ET 8-K
Capital Raise Blue Owl Credit Income Corp. OCIC

Blue Owl Credit Income Capital Raise of $1.75M

Blue Owl Credit Income Corp. sold 191,466 unregistered Class I common shares for $1.75 million in a private placement to feeder vehicles. The company also provided an update on its continuous public offering, which has raised approximately $22.5 billion in total proceeds to date across its public and private offerings.

Value
$1.75M
Counterparty
feeder vehicles
4:14 PM ET 8-K
Court & Legal Update Sarepta Therapeutics, Inc. SRPT

Sarepta Therapeutics Court & Legal Update

Sarepta Therapeutics entered into a settlement agreement with REGENXBIO, the University of Pennsylvania, and Catalent to resolve pending patent infringement litigation regarding the '274 and '617 patents. Sarepta will pay a lump sum of $39.0 million to REGENXBIO in exchange for a release of claims and a covenant not to sue regarding Sarepta's gene therapy products using the AAVrh74-based capsid, including ELEVIDYS. The settlement resolves all pending litigations with prejudice and includes no admission of liability.

Counterparty
REGENXBIO Inc.
4:14 PM ET 8-K
Capital Raise Leader's Advantage Acquisition Corp. LEDR

Leader's Advantage Acquisition Capital Raise of $150M

Leader’s Advantage Acquisition Corp. consummated its initial public offering (IPO) of 15,000,000 units at $10.00 per unit, generating gross proceeds of $150 million. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with the units trading on Nasdaq under the symbol LEDRU. The company has granted underwriters a 45-day option to purchase up to an additional 2,250,000 units to cover over-allotments.

Value
$150M
Counterparty
Clear Street LLC
4:12 PM ET 8-K
Clinical Trial Data Arcturus Therapeutics Holdings Inc. ARCT

Arcturus Therapeutics Holdings Clinical Trial Data

Arcturus Therapeutics released Phase 2 clinical data for ARCT-810, its mRNA-based therapeutic candidate for Ornithine Transcarbamylase (OTC) deficiency. The company also provided a strategic update on its broader mRNA delivery platform and technology pipeline.

4:11 PM ET 8-K
Loan & Debt Ready Capital Corp RC

Ready Capital $100M Debt Financing with U.S. Bank Trust Company, National Association

Ready Capital Corporation entered into a supplemental indenture to amend the terms of its $100 million 7.375% Senior Notes due 2027. The amendment, approved by a majority of noteholders, relaxes the Recourse Debt to Equity Ratio to 2.0 to 1.0 and adjusts the minimum Consolidated Net Asset Value covenant to $1.2 billion plus equity activity adjustments.

Value
$100M
Counterparty
U.S. Bank Trust Company, National Association
Term
through 2027
4:11 PM ET 8-K
Reverse Stock Split Vsee Health, Inc. VSEE

Vsee Health Reverse Stock Split

VSee Health, Inc. has filed a Certificate of Amendment to effect a 1-for-80 reverse stock split of its common stock, effective September 23, 2026. The stock will begin trading on a split-adjusted basis on September 24, 2026, under a new CUSIP number. No fractional shares will be issued, with any resulting fractions rounded up to the next whole number.

4:10 PM ET 8-K
Dividend Blue Owl Technology Income Corp. OTIC

Blue Owl Technology Income Dividend

Blue Owl Technology Income Corp. declared monthly distributions for its Class S, Class D, and Class I shares, with a gross distribution of $0.074775 per share payable in October and November 2026. The filing also provided a routine update on its continuous public offering, which has raised approximately $4.07 billion to date, and reported an August 31, 2026 net asset value (NAV) of $9.75 per share across all classes.

4:07 PM ET 8-K
Reverse Stock Split Marimed Inc. MRMD

Marimed Reverse Stock Split

MariMed Inc. has filed a definitive proxy statement for a special meeting of stockholders to seek approval for a reverse stock split at a ratio between 1-for-50 and 1-for-100. The move is intended to increase the share price to satisfy listing requirements for a potential move to a major U.S. national securities exchange. The special meeting is scheduled for October 28, 2026.

4:06 PM ET 8-K
Other 8-K Filing Gossamer Bio, Inc. GOSS

Gossamer Bio Other 8-K Filing

Gossamer Bio has submitted its first New Drug Application (NDA) to the FDA for seralutinib for the treatment of pulmonary arterial hypertension (PAH). The submission is supported by data from the Phase 3 PROSERA and Phase 2 TORREY studies, following a Pre-NDA meeting with the regulator in June 2026. The FDA is expected to determine whether to accept the application for filing later this year.

Counterparty
FDA

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.